AroCell AB (publ) (AROC.ST)
SEK 0.56
(1.83%)
SEK 0.56
(1.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.75 Million SEK | -13.5% |
| 2022 | -12.94 Million SEK | 73.54% |
| 2021 | -30.26 Million SEK | -90.34% |
| 2020 | -23.73 Million SEK | -15.99% |
| 2019 | -20.47 Million SEK | 0.1% |
| 2018 | -20.51 Million SEK | -20.19% |
| 2017 | -15 Million SEK | -87.28% |
| 2016 | -9.22 Million SEK | -23.65% |
| 2015 | -7.45 Million SEK | -18.4% |
| 2014 | -6.29 Million SEK | -72.43% |
| 2013 | -3.65 Million SEK | -19.47% |
| 2012 | -3.05 Million SEK | 11.82% |
| 2011 | -3.46 Million SEK | -71.36% |
| 2010 | -2.02 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -10.77 Million SEK | 101.7% |
| 2024 Q3 | -7.58 Million SEK | 41.88% |
| 2024 Q2 | -13.29 Million SEK | -44725.64% |
| 2023 FY | - SEK | -13.5% |
| 2023 Q3 | -13.26 Million SEK | 14.34% |
| 2023 Q2 | -15.48 Million SEK | -13.29% |
| 2023 Q4 | -16.86 Million SEK | -27.13% |
| 2023 Q1 | -13.66 Million SEK | 17.25% |
| 2022 Q1 | -15.69 Million SEK | 21.5% |
| 2022 Q4 | -16.51 Million SEK | -49.26% |
| 2022 Q3 | -11.06 Million SEK | 30.89% |
| 2022 Q2 | -16.01 Million SEK | -2.05% |
| 2022 FY | - SEK | 73.54% |
| 2021 Q1 | -6.07 Million SEK | -1.08% |
| 2021 Q3 | -17.77 Million SEK | -164.23% |
| 2021 Q4 | -19.99 Million SEK | -12.47% |
| 2021 FY | - SEK | -90.34% |
| 2021 Q2 | -6.72 Million SEK | -10.7% |
| 2020 Q1 | -5.47 Million SEK | 9.27% |
| 2020 Q4 | -6.01 Million SEK | 5.62% |
| 2020 FY | - SEK | -15.99% |
| 2020 Q3 | -6.37 Million SEK | -2.82% |
| 2020 Q2 | -6.19 Million SEK | -13.17% |
| 2019 Q4 | -6.03 Million SEK | -34.08% |
| 2019 Q3 | -4.5 Million SEK | 8.44% |
| 2019 FY | - SEK | 0.1% |
| 2019 Q1 | -5.28 Million SEK | 3.21% |
| 2019 Q2 | -4.91 Million SEK | 7.04% |
| 2018 Q1 | -4.18 Million SEK | 27.39% |
| 2018 Q2 | -5.71 Million SEK | -36.59% |
| 2018 FY | - SEK | -20.19% |
| 2018 Q4 | -5.46 Million SEK | -1.16% |
| 2018 Q3 | -5.4 Million SEK | 5.46% |
| 2017 Q4 | -5.75 Million SEK | -56.59% |
| 2017 FY | - SEK | -87.28% |
| 2017 Q3 | -3.67 Million SEK | -2.0% |
| 2017 Q2 | -3.6 Million SEK | 14.65% |
| 2017 Q1 | -4.22 Million SEK | -62.57% |
| 2016 FY | - SEK | -23.65% |
| 2016 Q1 | -2.84 Million SEK | -75.25% |
| 2016 Q2 | -1.9 Million SEK | 33.1% |
| 2016 Q3 | -2.58 Million SEK | -36.26% |
| 2016 Q4 | -2.59 Million SEK | -0.38% |
| 2015 FY | - SEK | -18.4% |
| 2015 Q2 | -1.63 Million SEK | 31.61% |
| 2015 Q1 | -2.39 Million SEK | 12.35% |
| 2015 Q4 | -1.62 Million SEK | 10.17% |
| 2015 Q3 | -1.8 Million SEK | -10.13% |
| 2014 Q1 | -1.1 Million SEK | 26.97% |
| 2014 Q4 | -2.73 Million SEK | -159.23% |
| 2014 FY | - SEK | -72.43% |
| 2014 Q3 | -1.05 Million SEK | 25.14% |
| 2014 Q2 | -1.4 Million SEK | -27.54% |
| 2013 FY | - SEK | -19.47% |
| 2013 Q1 | -849 Thousand SEK | 16.93% |
| 2013 Q4 | -1.51 Million SEK | -247.51% |
| 2013 Q3 | -435 Thousand SEK | 49.24% |
| 2013 Q2 | -857 Thousand SEK | -0.94% |
| 2012 Q1 | -709 Thousand SEK | 38.35% |
| 2012 Q2 | -866 Thousand SEK | -22.14% |
| 2012 Q4 | -1.02 Million SEK | -95.41% |
| 2012 Q3 | -523 Thousand SEK | 39.61% |
| 2012 FY | - SEK | 11.82% |
| 2011 Q2 | -1.18 Million SEK | -80.4% |
| 2011 Q3 | -472 Thousand SEK | 60.24% |
| 2011 FY | - SEK | -71.36% |
| 2011 Q1 | -658 Thousand SEK | -15.57% |
| 2011 Q4 | -1.15 Million SEK | -143.64% |
| 2010 Q3 | -562 Thousand SEK | -5.44% |
| 2010 Q2 | -533 Thousand SEK | 0.0% |
| 2010 Q4 | -569.34 Thousand SEK | -1.31% |
| 2010 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | -43.8 Million SEK | 68.587% |
| Immunovia AB (publ) | -166.55 Million SEK | 91.739% |
| Prostatype Genomics AB (publ) | -38.02 Million SEK | 63.811% |
| SenzaGen AB | -13.53 Million SEK | -1.647% |
| Spermosens AB | -10.7 Million SEK | -28.541% |